Abstract
In 1969, Patel and Terasaki demonstrated the role of crossmatching in solid organ transplantation ( 1 Patel R. Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969; 280: 735-739 Crossref PubMed Scopus (1237) Google Scholar ). In this landmark study, 24 of 30 kidney transplant recipients who had a positive crossmatch had immediate graft failure demonstrating that cytotoxic donor-specific antibodies (DSA) are a strong contraindication to transplantation ( 1 Patel R. Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969; 280: 735-739 Crossref PubMed Scopus (1237) Google Scholar ). Since then, methods to identify HLA antibodies and their specificities have improved significantly, and the widespread use of the virtual crossmatch made hyperacute rejection exceedingly rare. However, sensitive antibody detection assays such as single antigen bead assay (SAB) identify more allosensitized patients, but it has become increasingly clear that not all HLA antibodies have the same deleterious effect on the allograft. This emphasizes the importance of close collaboration between clinicians and the HLA laboratory in managing allosensitized patients. Outcomes after flow cytometry crossmatch-positive lung transplants managed with perioperative desensitizationAmerican Journal of TransplantationPreviewOur program previously reported successful outcomes after virtual crossmatch (VXM)-positive lung transplants managed with perioperative desensitization, but our ability to stratify their immunologic risk was limited without flow cytometry crossmatch (FCXM) data before 2014. The aim of this study was to determine allograft and chronic lung allograft dysfunction (CLAD)-free survival after VXM-positive/FCXM-positive lung transplants, which are performed at a minority of programs owing to the high immunologic risk and lack of data on outcomes. Full-Text PDF Lung transplantation despite preformed donor-specific antihuman leukocyte antigen antibodies: a 9-year single-center experienceAmerican Journal of TransplantationPreviewPretransplant allosensitization to human leukocyte antigens (HLA) increases the recipient’s waiting list time and mortality in lung transplantation. Rather than waiting for crossmatch-negative donors, since 2013, recipients with preformed donor-specific antiHLA antibodies (pfDSA) have been managed with repeated IgA- and IgM-enriched intravenous immunoglobulin (IgGAM) infusions, usually in combination with plasmapheresis before IgGAM and a single dose of antiCD20 antibody. This retrospective study presents our 9-year experience with patients transplanted with pfDSA. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
